Remove tag certain-health
article thumbnail

Grand Rounds October 20, 2023: A National Initiative to Eliminate Hepatitis C in the United States – Why This Matters to Clinical Trialists (Rachael L. Fleurence, PhD, MSc; Joshua M. Sharfstein, MD)

Rethinking Clinical Trials

Fleurence, PhD, MSc Senior Advisor National Institutes of Health Joshua M. PCORnet has been an important resource by executing a query to identify the volume of HCV tests conducted by participating health systems and the number of co-infections with Hepatitis B virus.       Speakers Rachael L. A manuscript is under development.

article thumbnail

Grand Rounds Biostatistics Series January 5, 2024: Methods for Handling Missing Data in Cluster Randomized Trials (Rui Wang, PhD; Moderator: Fan Li, PhD)

Rethinking Clinical Trials

Across these situations, treating certain aspects at zero would cause these examples not to be what we’re targeting. When we fit different model, we would look at the tool missing, the gamma parameter, or maybe the AGA parameter depending on the model and whether the individual outcome is missing or not.

Trials 275
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Grand Rounds June 30, 2023: Decentralized Trials – From Guidance to Reality & What’s Left (Adrian Hernandez, MD, MHS; Pamela Tenaerts, MD, MPH; Craig Lipset, MPH)

Rethinking Clinical Trials

While similar to the FDA draft guidance, the EMA guidance differs slightly in its emphasis and lack of certain topics. For instance, there is no discussion of the role of the health care provider in the DCTs, but it emphasizes the importance of patient voice.

Trials 130
article thumbnail

Grand Rounds Ethics and Regulatory Series September 9, 2022: Building An Academic Learning Health System: Why Is It So Hard? (Steven Joffe, MD, MPH)

Rethinking Clinical Trials

Department of Medical Ethics & Health Policy. Ethics, Learning Health System. Academic medical institutions may seem like the natural setting to build Learning Health Systems (LHS), but they face unique structural barriers that require leadership, focus, and intentionality to overcome. Art and Ilene Penn Professor and Chair.

article thumbnail

Are RXBars Healthy? An In-Depth Look at the Trending Protein Bar

XTalks

RXBars have become a focal point in the protein bar sector, primarily driven by a surge in health-conscious consumers. So, what justifies such a hefty price tag and are RXBars healthy? Understanding the Components A key component of a balanced diet is fiber since it aids in digestion, promotes gut health and can lower cholesterol.

Protein 59
article thumbnail

Grand Rounds Ethics and Regulatory Series January 13, 2023: Ethical Considerations When Vulnerable Populations are Subjects in Pragmatic Trials (Emily A. Largent, JD, PhD, RN)

Rethinking Clinical Trials

Many pragmatic clinical trials are conducted with waivers of informed consent, but when vulnerable populations are subjects in research, there may still be additional important considerations, such as outreach, identifying caregivers through the medical record, and being certain a diagnosis of dimension has already been disclosed to the patient.

Trials 130
article thumbnail

Preview of Pharma Commercials at Super Bowl 2024: From Touching Down with TUMS to Tackling Menopause

XTalks

While direct-to-consumer (DTC) TV advertising remains a mainstay marketing strategy in pharma, ads have mostly been relegated to evening hours during certain programs for older audiences. Genevieve Neal-Perry Discusses New Trial Data for Astellas’ Menopause Drug Fezolinetant (Veozah) – Xtalks Life Science Podcast Ep.